ProKidney Reports Fourth Quarter Financial Results and

WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...

Related Keywords

Austria ,France ,Belgium ,Singapore ,Canada ,United Kingdom ,Spain ,Ukraine ,Taiwan ,United States ,Americans ,America ,Lee Roth ,Asia Pacific ,Tim Bertram ,Selina Husain Robert Flamm ,Joseph Stavas ,Dburns Mcclellan ,Glenn Schulman ,Prokidney Corp ,Society Of Interventional Radiology ,Capital Suvretta Holding Corp ,Drug Administration ,Health Canada ,Clinical Development Updates ,European Medicines Agency ,Exchange Commission ,Company Class ,Head Of Global Clinical Development ,Healthcare Products Regulatory Agency ,Nasdaq ,Chief Executive Officer ,Global Clinical Development ,Interventional Procedures ,Corporate Highlights ,Clinical Development ,United Kingdom Medicines ,Taiwan Food ,Latin America ,Interventional Radiology ,Marketing Authorization ,Social Capital Suvretta Holding ,Loss Before Noncontrolling Interest ,Renal Autologous Cell Therapy ,Regenerative Medicine Advanced Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Robert Flamm ,Months Ended December ,Ended December ,Business Combination ,Nasdaq Prok ,Prokidney ,